Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method

被引:4
|
作者
Sanada, Hideaki [1 ]
Kobayashi, Kazuki [1 ]
Oyama, Kenji [1 ]
Maru, Takamitsu [1 ]
Nakanishi, Takeshi [1 ]
Umetsu, Mitsuo [1 ]
Asano, Ryutaro [1 ,2 ]
Kumagai, Izumi [1 ]
机构
[1] Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan
[2] Tokyo Univ Agr & Technol, Grad Sch Engn, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
RESHAPING HUMAN-ANTIBODIES; BISPECIFIC ANTIBODY; THERMODYNAMIC CONSEQUENCES; CANCER-IMMUNOTHERAPY; MONOCLONAL-ANTIBODY; DISPLAY SYSTEM; DOMAIN ORDER; DIABODY; EGFR; STABILIZATION;
D O I
10.1038/s41598-018-23796-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Affinity maturation is one of the cardinal strategies for improving antibody function using in vitro evolutionary methods; one such well-established method is phage display. To minimise gene deletion, we previously developed an open sandwich (OS) method wherein selection was performed using only phage-displaying VH fragments after mixing with soluble VL fragments. The decrease in anti-EGFR antibody 528 affinity through humanization was successfully recovered by selecting VH mutants using this OS method. However, the affinity was not similar to that of parental 528. For further affinity maturation, we aimed to isolate VL mutants that act in synergy with VH mutants. However, the OS method could not be applied for selecting VL fragments because the preparation of soluble VH fragments was hampered by their instability and insolubility. Therefore, we initially designed a modified OS method based on domain-swapping of VH fragments, from added soluble Fv fragments to phagedisplaying VL fragments. Using this novel Fv-added OS selection method, we successfully isolated VL mutants, and one of the Fv comprising VH and VL mutants showed affinity almost equivalent to that of parental 528. This method is applicable for engineering other VL fragments for affinity maturation.
引用
收藏
页数:9
相关论文
共 45 条
  • [41] In vivo study of anti-epidermal growth factor receptor antibody-based iron oxide nanoparticles (anti-EGFR-SPIONs) as a novel MR imaging contrast agent for lung cancer (LLC1) cells detection
    Shahbazi-Gahrouei, Daryoush
    Abdi, Negar
    Shahbazi-Gahrouei, Saghar
    Hejazi, Seyed Hossein
    Salehnia, Zeinab
    IET NANOBIOTECHNOLOGY, 2020, 14 (05) : 369 - 374
  • [42] Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients
    Huang, Lulu
    Liu, Zhenfang
    Deng, Donghong
    Tan, Aihua
    Liao, Ming
    Mo, Zengnan
    Yang, Xiaobo
    ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (01) : 1 - 9
  • [43] PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
    Sood, Arjun
    McClain, Danielle
    Maitra, Radhashree
    Basu-Mallick, Atrayee
    Seetharam, Raviraja
    Kaubisch, Andreas
    Rajdev, Lakshmi
    Mariadason, John M.
    Tanaka, Kathryn
    Goel, Sanjay
    CLINICAL COLORECTAL CANCER, 2012, 11 (02) : 143 - 150
  • [44] Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)
    Arabpour, Mohammad
    Poelstra, Klaas
    Helfrich, Wijnand
    Bremer, Edwin
    Haisma, Hidde J.
    JOURNAL OF GENE MEDICINE, 2014, 16 (9-10) : 281 - 290
  • [45] Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model
    Ramezani-Aliakbari, Khadijeh
    Khaki-Bakhtiarvand, Vahid
    Mahmoudian, Jafar
    Asgarian-Omran, Hossein
    Shokri, Fazel
    Hojjat-Farsangi, Mohammad
    Jeddi-Tehrani, Mahmood
    Shabani, Mahdi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 121